Definitive re‑irradiation of locally recurrent esophageal cancer after trimodality therapy in patients with a poor performance status

Kim,Daniel   W.; Raoof,Sana; Lamba,Nayan; Lee,Grace; Bitterman,Danielle   S.; Mahal,Amandeep   R.; Sanford,Nina   N.; Lam,Miranda   B.; Mamon,Harvey   J.

doi:10.3892/mco.2020.2044

July-2020 Volume 13 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2020 Volume 13 Issue 1

Full Size Image

Article Open Access

Definitive re‑irradiation of locally recurrent esophageal cancer after trimodality therapy in patients with a poor performance status

Authors:
- Daniel W. Kim
- Sana Raoof
- Nayan Lamba
- Grace Lee
- Danielle S. Bitterman
- Amandeep R. Mahal
- Nina N. Sanford
- Miranda B. Lam
- Harvey J. Mamon
View Affiliations / Copyright

Affiliations: Department of Radiation Oncology, Dana‑Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA 02115, USA, Harvard Medical School, Boston, MA 02115, USA, Yale School of Medicine, New Haven, CT 06510, USA, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 27-32
|
Published online on: May 11, 2020

https://doi.org/10.3892/mco.2020.2044
Expand metrics +

Abstract

There are few treatment guidelines for locally recurrent esophageal cancer after trimodality treatment (pre‑operative chemoradiation followed by surgery) in patients with a poor performance status. The purpose of this single institutional, retrospective study was to evaluate the clinical outcomes and toxicities of definitive‑intent re‑irradiation for patients with recurrent esophageal cancer with a poor performance status [ECOG (Eastern Cooperative Oncology Group) ≥2]. Seven patients were identified with a median age of 74 years (range, 61‑81 years). Four patients were ECOG 2 and three patients were ECOG 3. The median follow‑up time after re‑irradiation was 49 months. The median interval between initial radiotherapy and re‑treatment was 32 months. Six patients received concurrent chemotherapy [carboplatin + paclitaxel in three patients; folinic acid, fluorouracil, oxaliplatin (FOLFOX) + 5‑fluorouracil in one patient; FOLFOX in one patient, and capecitabine in one patient]. At the last follow‑up, the six patients who underwent concurrent chemotherapy had stable disease (86%), while the one who did not receive chemotherapy progressed (14%). Two patients developed metastases. Three patients developed acute (<6 months) grade 4 toxicities (dysphagia, anemia, esophagitis). There were no early deaths attributable to treatment. Late toxicities (>6 months) were limited to grades 1 and 2 dysphagia and pneumonitis in four patients. In conclusion, definitive re‑irradiation of recurrent esophageal cancer in patients with a poor performance status appears to be safe with acceptable acute toxicity and late complications. It also appears to result in durable local control when combined with chemotherapy, albeit with a small number of patients and limited follow‑up.

View Figures

View References

1	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.PubMed/NCBI View Article : Google Scholar
2	Chen Y, Lu Y, Wang Y, Yang H, Xia Y, Chen M, Song H, Li T, Li D, Wang J, et al: Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. Dis Esophagus. 27:134–140. 2013.PubMed/NCBI View Article : Google Scholar
3	Kim YS, Lee CG, Kim KH, Kim T, Lee J, Cho Y and Koom WS: Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy. Radiat Oncol J. 30:182–188. 2012.PubMed/NCBI View Article : Google Scholar
4	Yamashita H, Jingu K, Niibe Y, Katsui K, Matsumoto T, Nishina T and Terahara A: Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: A Japanese multi-institutional study of 237 patients. Radiat Oncol. 12(38)2017.PubMed/NCBI View Article : Google Scholar
5	Nieder C, Grosu AL, Andratschke NH and Molls M: Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. Int J Radiat Oncol Biol Phys. 61:851–855. 2005.PubMed/NCBI View Article : Google Scholar
6	Nieder C, Grosu AL, Andratschke NH and Molls M: Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Radiat Oncol Biol Phys. 66:1446–1449. 2006.PubMed/NCBI View Article : Google Scholar
7	Katano A, Yamashita H and Nakagawa K: Re-irradiation of locoregional esophageal cancer recurrence following definitive chemoradiotherapy: A report of 6 cases. Mol Clin Oncol. 7:681–686. 2017.PubMed/NCBI View Article : Google Scholar
8	Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358:36–46. 2008.PubMed/NCBI View Article : Google Scholar
9	Lassig AA, Joseph AM, Lindgren BR, Fernandes P, Cooper S, Schotzko C, Khariwala S, Reynolds M and Yueh B: The effect of treating institution on outcomes in head and neck cancer. Otolaryngol Head Neck Surg. 147:1083–1092. 2012.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Definitive re‑irradiation of locally recurrent esophageal cancer after trimodality therapy in patients with a poor performance status

This article is mentioned in:

Abstract

Related Articles